塞德斯医疗 CLDX 深 沪
等待开盘 11-04 09:30:00 美东时间
24.75
-1.980
-7.41%
华盛通- 最 高26.80
- 今 开26.46
- 成交量 134.41万股
- 最 低 24.40
- 昨 收 26.73
- 总市值 16.44亿
- 52周最高 29.05
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.40
- 委 比 -79.35%
- 总股本 6640.65万
- 历史最高 582.60
- 量 比 1.77
- 振 幅 8.98%
- 历史最低 1.50
- 每 手 1
- 风险率 2.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celldex Releases Phase 1 Results For Its Bispecific Antibody CDX-622 Showing Drug Was Well Tolerated, Showed Favorable Pharmacokinetics, And Led To Rapid, Sustained Reductions In Serum Tryptase, Confirming Effective Mast Cell Inhibition
Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and
10-31 04:14
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
<p>Calidi Biotherapeutics announced the formation of its Scientific Advisory Board (SAB) to advance its RedTail platform and lead candidate CLD-401. The RedTail platform uses an enveloped vaccinia virus to deliver genetic medicines systemically and target metastatic sites. CLD-401 aims to replicate in tumors, induce immune responses, and express IL-15 superagonist. The SAB includes leading experts in drug development and oncology. The company is ...
10-22 12:00
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Mizuho Initiates Coverage On Celldex Therapeutics with Outperform Rating, Announces Price Target of $48
Mizuho analyst Joseph Catanzaro initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating and announces Price Target of $48.
10-21 20:44
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Analyst Expectations For Celldex Therapeutics's Future
Analysts' ratings for Celldex Therapeutics (NASDAQ:CLDX) over the last quarter ...
10-14 04:01
Barclays Initiates Coverage On Celldex Therapeutics with Underweight Rating, Announces Price Target of $25
Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announces Price Target of $25.
10-13 20:17
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study
Eupraxia's Cohort 9 RESOLVE trial data showed durable remission, improved tissue health, and strong safety, supporting Phase 2b expansion.
09-30 22:40
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Maintains $62 Price Target
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $62 price target.
09-17 21:35
